• News
  • Perspectives
  • September 29, 2017 – Clarion attended two important but very different oncology meetings in September: the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, and the Friends of Cancer Research 2017 Blueprint for Breakthrough forum in Washington, DC. From ESMO—the largest European annual meeting of oncology professionals and researchers—Clarion reviewed a broad set of new data, including important advances in combination therapies and adjuvant therapies, and attended important discussions on biomarker development and approaches to rein in the cost of cancer care. At the Friends forum—an intimate meeting focused on “Charting the Course for Precision Medicine”—Clarion witnessed lively discussion among FDA, industry, academic, and non-profit stakeholders on key challenges with the development, approval process, and adoption of novel molecular tests in oncology.

    ESMO 2017 Highlights

    FOCR Blueprint 2017 Precision Medicine Summary

    June 20, 2017 –
     Clarion’s oncology team highlights some of the major themes emerging from the 2017 ASCO Annual Meeting: immuno-oncology combinations, advances in novel I-O mechanisms, tissue-agnostic drug development, and the struggles that oncology practices are having with MACRA.

    ASCO 2017 Highlights by Clarion Healthcare – final

    April 14, 2017 – The AACR Annual Meeting 2017 marked its 110th anniversary with record-breaking attendance and many thousands of presentations and posters. A Clarion team was there in DC to take in the latest advances in cancer research, and we present here some perspectives and highlights across four major themes: new hope for early cancer detection; advances in targeted therapy; the continued rise of immunotherapy; and large-scale initiatives aimed at marrying genomics with clinical data.

    AACR 2017 Highlights FINAL

    February 2, 2017 – Precision medicine—the rational selection of treatments for specific patient subgroups—has become a cornerstone of oncology. Time and again, drugs acting on specific molecular targets have transformed the treatment of cancers defined by those targets: endocrine therapies for breast cancer defined by hormone receptor expression; Herceptin (trastuzumab) for breast cancer defined by HER2 overexpression; Gleevec (imatinib) for chronic myeloid leukemia defined by the BCR-ABL fusion gene; Xalkori (crizotinib) for lung cancer defined by ALK fusion; and Zelboraf (vemurafenib) for melanoma defined by BRAF activating mutations, are just some of the prominent examples.  

    Termeer Center Roundtable – Precision Medicine 2.0 – Clarion summary 2017-02-08 FINAL

    December 19, 2016 – Members of the Clarion Healthcare oncology team attended the ASH Annual meeting in San Diego last week, capturing highlights from the conference and synthesizing key outcomes on our website.  Take a look at data emerging from the CAR-T race, PD1 inhibitor trials, and targeted therapy combination studies.  


    September 7, 2016 – Clarion Healthcare in collaboration with Dr. Keith Flaherty recently published an article in Cancer Discovery about the CoNNCT Initiative, a new paradigm designed to alleviate the bottleneck in novel-novel combination therapies in oncology.  Cancer Discovery is a leading peer-reviewed journal in oncology and the highest impact factor AACR journal. This article is aimed at a scientific and clinical readership; Clarion and Dr. Flaherty published a previous article about CoNNCT in the April issue of In Vivo, aimed at a biopharmaceutical and business intelligence-oriented audience.

    Cancer Discovery September 2016

    June 16, 2016 – Clarion’s oncology team highlights themes and shares perspectives from the 2016 ASCO conference held earlier this month in Chicago.

    ASCO 2016 Highlights 

    March, 2016 –  Dennis Chang, Uciane Scarlett, Jessica Blaustein and Sohini Mazumdar from Clarion attended the Termeer Center Roundtable at MGH, in which a panel of distinguished experts discussed emerging solutions to overcome the challenges of immunotherapy.  We share highlights — and a proposal for moving forward — from the panel discussion here.

    Termeer Center Roundtable 2016

    April 29, 2016 – Optimism pervaded the 2016 AACR Conference, fueled by the continued emergence of encouraging immunotherapy data along with foundational advances in fields of study including cancer epigenetics, cellular metabolism and new applications of gene editing tools such as CRISPR/Cas9.  Read highlights and themes emerging from the conference here.

    AACR 2016 Highlights

    May 5, 2016 – Combination therapies are the cornerstone of oncology, but the development model has been slow to shift to early testing of combinations of investigational drugs.  The CoNNCT initiative aims to accelerate clinical testing of novel-novel combinations, and in doing so provide benefits for biopharma, clinicians and the cancer patients they serve.

    CoNNCT In Vivo April 2016

    Home | Contact | Terms & Conditions | Login

    © 2011 - Clarion Healthcare - All Rights Reserved